Lumbar Spinal Fusion Policy
Policy governs medical necessity review and site-of-service determination for elective single-level lumbar spinal fusion in adults (age 19+), including indications, documentation requirements, coding, and definitions. It specifies conditions when single-level fusion may be considered medically necessary, conditions considered not medically necessary or investigational, and site-of-service criteria for elective surgical procedures.
Historical policy revisions clarified instability thresholds (e.g., addition of 4 mm translational instability in 09/11/12 history entry) and added CPT codes 22633 and 22634 on 01/11/12.
Annual literature reviews and guideline incorporations noted through 2024 references (NASS 2021, AAOS 2021, NICE 2017).
CPT codes 22633 and 22634 were added (01/11/12).
Policy statements extensively revised to clarify instability (added 4 mm translational instability), spinal stenosis, and pseudoarthrosis; failure of 6 months nonsurgical care removed from all policy statements (09/11/12).
Definitions for truncal imbalance, spondylolisthesis, and pseudoarthrosis added (multiple dates 2012-2016).
Smoking within the previous 6 weeks is a contraindication for lumbar spinal fusion; documentation of cessation required (04/14/15 update).
Diagnostic imaging (CT, MRI) must be performed within 12 months of surgery for documentation review (12/08/15).
CPT codes 22853, 22854, and 22859 added replacing deleted 22851 effective 01/01/17.
CPT code 62290 removed (10/01/17) and 0309T removed (01/01/19).
Policy title changed to 'Lumbar Spinal Fusion in Adults' and juvenile/adolescent scoliosis criteria removed (12/01/21).
Medically necessary statement for revision surgery for implant/instrumentation failure added effective for dates of service on or after September 2, 2022.
Multiple-level lumbar spinal fusion declared not medically necessary when criteria are not met for all levels (12/01/23).
Reorganized criteria for recurrent (same level) disc herniation to call out rapidly progressive symptoms of motor loss, neurogenic claudication, or cauda equina syndrome as stand-alone criteria (03/01/24).
Annual literature review updates noted repeatedly; most recent literature review through July 17, 2024 added (12/01/24).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.